The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer

Overview

Journal MedComm (2020)

Specialty Health Services

Date 2025 Mar 11

PMID 40066231

Authors

Bing Zhong

Jintao Du

Feng Liu

Silu Sun

Affiliations

Soon will be listed here.

Abstract

Yes-associated protein (YAP) plays a central role in the Hippo pathway, primarily governing cell proliferation, differentiation, and apoptosis. Its significance extends to tumorigenesis and inflammatory conditions, impacting disease initiation and progression. Given the increasing relevance of YAP in inflammatory disorders and cancer, this study aims to elucidate its pathological regulatory functions in these contexts. Specifically, we aim to investigate the involvement and molecular mechanisms of YAP in various inflammatory diseases and cancers. We particularly focus on how YAP activation, whether through Hippo-dependent or independent pathways, triggers the release of inflammation and inflammatory mediators in respiratory, cardiovascular, and digestive inflammatory conditions. In cancer, YAP not only promotes tumor cell proliferation and differentiation but also modulates the tumor immune microenvironment, thereby fostering tumor metastasis and progression. Additionally, we provide an overview of current YAP-targeted therapies. By emphasizing YAP's role in inflammatory diseases and cancer, this study aims to enhance our understanding of the protein's pivotal involvement in disease processes, elucidate the intricate pathological mechanisms of related diseases, and contribute to future drug development strategies targeting YAP.

References

Aylon Y, Oren M . Tumor Suppression by p53: Bring in the Hippo!. Cancer Cell. 2017; 32(4):397-399. DOI: 10.1016/j.ccell.2017.09.010. View

Widemann B, Italiano A . Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. J Clin Oncol. 2017; 36(2):160-167. PMC: 5759316. DOI: 10.1200/JCO.2017.75.3467. View

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

Li F, Xu Y, Liu B, Singh P, Zhao W, Jin J . YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res. 2018; 25(7):2264-2277. DOI: 10.1158/1078-0432.CCR-18-1029. View

Alexander E, Cibas E . Diagnosis of thyroid nodules. Lancet Diabetes Endocrinol. 2022; 10(7):533-539. DOI: 10.1016/S2213-8587(22)00101-2. View

Bado I, Zhang X . Senesce to Survive: YAP-Mediated Dormancy Escapes EGFR/MEK Inhibition. Cancer Cell. 2020; 37(1):1-2. DOI: 10.1016/j.ccell.2019.12.008. View

Pefani D, Pankova D, Abraham A, Grawenda A, Vlahov N, Scrace S . TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation. Mol Cell. 2016; 63(1):156-66. DOI: 10.1016/j.molcel.2016.05.012. View

Li Y, Feng J, Song S, Li H, Yang H, Zhou B . gp130 Controls Cardiomyocyte Proliferation and Heart Regeneration. Circulation. 2020; 142(10):967-982. DOI: 10.1161/CIRCULATIONAHA.119.044484. View

He T, Zhang Q, Xu P, Tao W, Lin F, Liu R . Extracellular vesicle-circEHD2 promotes the progression of renal cell carcinoma by activating cancer-associated fibroblasts. Mol Cancer. 2023; 22(1):117. PMC: 10362694. DOI: 10.1186/s12943-023-01824-9. View

10.

Zhao C, Gong J, Bai Y, Yin T, Zhou M, Pan S . A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Cell Death Differ. 2022; 30(1):1-15. PMC: 9883464. DOI: 10.1038/s41418-022-01040-w. View

11.

Taniguchi K, Wu L, Grivennikov S, de Jong P, Lian I, Yu F . A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015; 519(7541):57-62. PMC: 4447318. DOI: 10.1038/nature14228. View

12.

Razumilava N, Gores G . Cholangiocarcinoma. Lancet. 2014; 383(9935):2168-79. PMC: 4069226. DOI: 10.1016/S0140-6736(13)61903-0. View

13.

Nolan E, Lindeman G, Visvader J . Deciphering breast cancer: from biology to the clinic. Cell. 2023; 186(8):1708-1728. DOI: 10.1016/j.cell.2023.01.040. View

14.

Diamantopoulou Z, White G, Fadlullah M, Dreger M, Pickering K, Maltas J . TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. Cancer Cell. 2017; 31(5):621-634.e6. PMC: 5425402. DOI: 10.1016/j.ccell.2017.03.007. View

15.

Park Y, Sohn B, Johnson R, Kang M, Kim S, Shim J . Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 2015; 63(1):159-72. PMC: 4881866. DOI: 10.1002/hep.28223. View

16.

Yu F, Luo J, Mo J, Liu G, Kim Y, Meng Z . Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014; 25(6):822-30. PMC: 4075337. DOI: 10.1016/j.ccr.2014.04.017. View

17.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

18.

Mieli-Vergani G, Vergani D . Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol. 2011; 8(6):320-9. DOI: 10.1038/nrgastro.2011.69. View

19.

Su D, Li Y, Zhang W, Gao H, Cheng Y, Hou Y . SPTAN1/NUMB axis senses cell density to restrain cell growth and oncogenesis through Hippo signaling. J Clin Invest. 2023; 133(20). PMC: 10575737. DOI: 10.1172/JCI168888. View

20.

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View